A new drug helps to delay the need for a wheelchair in multiple sclerosis
At the Congress of the European Academy of Neurology held in Lisbon, Roche representatives released new data on Ocrewus (ocrelizumab), a drug intended for patients with a primary progressive form of multiple sclerosis.
Recall that until recently in our country there were no medications for patients with this type of disease. However, ocrelizumab was recently registered in Russia. Ocervus is a drug based on monoclonal antibodies that selectively affect CD20 (+) B cells. It is believed that these cells are involved in the autoimmune destruction of myelin sheaths of nerve endings, which leads to a worsening of the condition of patients with multiple sclerosis.
The drug is intended for intravenous administration: within six months, patients should receive two infusions of okecrezumab every month.
Analysis of phase III clinical trials showed that taking medication slows disability – delaying for 7 years the continuing need for patients with multiple sclerosis in a wheelchair.
“For patients with primary progressive multiple sclerosis, whose disability progresses twice as fast as with relapsing multiple sclerosis, seven additional years without the need for a wheelchair can extend the time during which they can live independently in their home, continue working or care for their families, “says Helmut Butzkueven, professor, head of the Department of Multiple Sclerosis and Neuroimmunological Research at the Central Clinical School of the University of M Our, head of PC service and Neuroimmunology at Alfred Health and Director of the RS service in Eastern Health.